Vozmozhnosti korrektsii giperurikemii lozartanom u patsientov s arterial'noy gipertenziey i podagroy
- Authors: Nedogoda SV1, Ledyaeva AA1, Chumachok EV1, Tsoma VV1
-
Affiliations:
- Issue: Vol 8, No 4 (2011)
- Pages: 64-68
- Section: Articles
- URL: https://journals.eco-vector.com/2075-082X/article/view/33167
- DOI: https://doi.org/10.26442/SG33167
- ID: 33167
Cite item
Full Text
Abstract
References
- Alderman MH. Uric acid and cardiovascular risk. Curr Opin Pharmacol 2002; 2: 126-30.
- Bengtsson C, Lapidus L, Stendahl C, Waldenstrom J. Hyperuricaemia and risk of cardiovascular disease and overall death. A 12-year follow-up of participants in the population study of women in Gothenburg. Sweden. Acta Med Scand 1988; 224: 549-55.
- Ford ES, Cook S, Choi HK. Serum concentrations of uric acid and the metabolic syndrome among US children and adolescents. Circulation 2007; 115: 2526-32.
- Alderman M, Aiyer KJ. Uric acid: role in cardiovascular disease and effects of losartan. Curr Med Res Opin 2004; 20 (3): 369-79.
- Bulpitt CJ. Serum uric acid in hypertensive patients. Br Heart J 1975; 37: 1210-5.
- Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 1999; 131: 7-13.
- Niskanen LK, Laaksonen DE, Nyyssonen K et al. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Arch Intern Med 2004; 164: 1546-51.
- Weir CJ, Muir SW, Walters MR, Lees KR. Serum urate as an independent predictor of poor outcome and future vascular events after acute stroke. Stroke 2003; 34: 1951-6.
- Bairaktari ET, Kakafika AI, Pritsivelis N et al. Hypouricemia in individuals admitted to an inpatient hospital-based facility. Am J Kidney Dis 2003; 41: 1225-32.
- Riedel A, Nelson M. Prevalence of co morbid conditions and prescription medication use among patients with gout and hyperuricemia in a managed care setting. J Clin Rheumatol 2004; 10 (6): 308-14.
- Hamada T, Hisatome I, Kinugasa Y et al. Effect of the angiotensin II receptor antagonist losartan on uric acid and oxypurine metabolism in healthy subjects. Intern Med 2002; 41: 793-7.
- Shahinfar S, Simpson R, Carides A et al. Safety of losartan in hypertensive patients with asymptomatic hyperuricemia. JASN 1997; 8: 322.
- Shahinfar S, Simpson RL, Carides AD et al. Safety of losartan in hypertensive patients with thiazide-induced hyperuricemia. Kidney Int 1999; 56: 1879-85.
- Daskalopoulou SS et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004; 66 (4): 1714-5.
- Daijiro U, Hiroaki K. Long-term effects of angiotensin II receptor antagonist losartan on uric acid metabolism in hyperuricemic patients. Gout Nucleic Acid Metab 2002; 26: 25-32.
- Quarantino CP, Di Sciacio N, Rucci C et al. The normal range of serum urate levels and of fractional urate excretion. Adv Exp Med Biol 1994; 370: 91-3.
- Takahashi S, Moriwaki Y. Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism. Ann Rheum Dis 2003; 62: 572-5.